Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Lung Disease

    Current Location

    Search
    Lung Disease
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Interstitial Lung Disease Clinical Trials

    Top Lung Clinical Trials

    Top Lung Cancer Clinical Trials

    Top Lung Adenocarcinoma Clinical Trials

    Top Small Cell Lung Cancer Clinical Trials

    Top Non-Small Cell Lung Cancer Clinical Trials

    Top Lung Cancer Clinical Trials near Chicago, IL

    Top Lung Cancer Clinical Trials near Houston, TX

    Top Lung Cancer Clinical Trials near Baltimore, MD

    Top Lung Cancer Clinical Trials near Glendale, AZ

    Top Lung Cancer Clinical Trials near Ventura, CA

    Top Lung Cancer Clinical Trials near Dallas, TX

    By Trial

    Patritumab Deruxtecan for Non-Small Cell Lung Cancer

    FAPI PET for Lung Fibrosis

    Exercise and Counseling for Lung Cancer Prevention

    APL-101 + Osimertinib for Non-Small Cell Lung Cancer

    ctDNA Assay for Lung Cancer

    Abemaciclib for Small Cell Lung Cancer

    Immunotherapy Combinations for Non-Small Cell Lung Cancer

    NIR Fluorescence-Guided Surgery for Early Stage Lung Cancer

    CivaSheet for Lung Cancer

    PVB-SABR for Lung Cancer

    Precision Radiotherapy for Non-Small Cell Lung Cancer

    Radiotherapy + Immunotherapy/PARP Inhibitor for Small Cell Lung Cancer

    Related Searches

    Top Treatment for Insulin Clinical Trials

    Top Fatty-liver Clinical Trials

    Top Miscarriage Clinical Trials

    Top Thalassemia Clinical Trials

    Rocatinlimab for Eczema

    Pembro + Olaparib with TMZ for Recurrent Glioblastoma

    Elacestrant + Trastuzumab Deruxtecan for Breast Cancer

    Manual Therapy for Chronic Neck Pain

    Microneedling for Burn Scars

    Minimal Shoes and Exercises for Plantar Fasciitis

    Niacin for Alzheimer's Disease

    Non-Invasive Neuromodulation for Chronic Obstructive Pulmonary Disease

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      73 Lung Disease Trials Near You

      Power is an online platform that helps thousands of Lung Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      BI 1015550 for Interstitial Lung Disease

      Columbus, Ohio
      This trial tests if BI 1015550 can help adults with certain progressive lung diseases. Participants take the medicine as tablets, and their lung function is checked over time to see if it improves. The study aims to find out if this new treatment can slow down the worsening of their lung condition.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1178 Participants Needed

      Sildenafil for Bronchopulmonary Dysplasia

      Columbus, Ohio
      This is a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD).

      Trial Details

      Trial Status:Active Not Recruiting
      Age:< 29

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      120 Participants Needed

      Inspiratory Muscle Training for Lung Transplant Recovery

      Columbus, Ohio
      This trial is testing a special breathing exercise device for people who have had a lung transplant. The device helps strengthen the muscles used for breathing. The goal is to help these patients breathe better, feel less tired, and improve their ability to do everyday activities.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Regular IMT Program, Impaired Cognition

      90 Participants Needed

      Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

      Columbus, Ohio
      Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Obstructive Airway, Cardiac Disease, Others
      Must Be Taking:Pirfenidone, Nintedanib

      576 Participants Needed

      Inhaled Treprostinil for Pulmonary Fibrosis

      Columbus, Ohio
      Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, IPF, Uncontrolled Cardiac Disease, Others
      Must Be Taking:Nintedanib, Pirfenidone

      698 Participants Needed

      Inhaled Treprostinil for Pulmonary Fibrosis

      Columbus, Ohio
      Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Lactation, Health Risk, Others

      1850 Participants Needed

      Alterra Prestent + SAPIEN 3 Valve for Heart Disease

      Columbus, Ohio
      To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated for treatment of pulmonary regurgitation (PR). Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Infection, Endocarditis, Drug Use, Others
      Must Not Be Taking:Antibiotics, Antiplatelets, Antithrombotics

      86 Participants Needed

      Ralinepag for Pulmonary Arterial Hypertension

      Columbus, Ohio
      This trial tests ralinepag, a medication for lung disease, on patients with PAH who participated in earlier research. It aims to improve blood flow in the lungs by relaxing blood vessels and reducing pressure.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Transplant, Others

      1000 Participants Needed

      Ralinepag for Pulmonary Arterial Hypertension

      Columbus, Ohio
      This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Severe Liver Disease, Renal Insufficiency, Malignancy, Others
      Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors

      1000 Participants Needed

      LY3537982 + Immunotherapy/Chemotherapy for Non-Small Cell Lung Cancer

      Columbus, Ohio
      This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:EGFR, ALK, BRAF, Others
      Must Be Taking:Folic Acid, Vitamin B12

      1016 Participants Needed

      BMS-986278 for Pulmonary Fibrosis

      Columbus, Ohio
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Idiopathic Pulmonary Fibrosis, Stroke, Heart Failure, Current Malignancy, Others
      Must Not Be Taking:Systemic Corticosteroids

      1092 Participants Needed

      Benralizumab for COPD

      Columbus, Ohio
      Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL). Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count. The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40 - 85

      Key Eligibility Criteria

      Disqualifiers:Asthma, Pulmonary Disease, Malignancy, Others
      Must Be Taking:ICS/LABA/LAMA

      689 Participants Needed

      Zipalertinib for Non-Small Cell Lung Cancer

      Columbus, Ohio
      This Trial is testing zipalertinib, a new drug, in patients with advanced lung cancer that has specific genetic changes. The drug aims to stop cancer growth by blocking faulty proteins. The study involves patients with different backgrounds and genetic profiles.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Seizures, Cardiac Disease, Others
      Must Not Be Taking:CYP3A4 Inducers, Inhibitors

      224 Participants Needed

      Neladalkib for Non-Small Cell Lung Cancer

      Columbus, Ohio
      Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Other Oncogenic Drivers, Cardiovascular Disease, Others
      Must Not Be Taking:ALK Inhibitors

      450 Participants Needed

      Aria CV System for Pulmonary Arterial Hypertension

      Columbus, Ohio
      This trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Renal Insufficiency, Scleroderma, Others
      Must Be Taking:PH Specific Medications

      30 Participants Needed

      Repotrectinib for Solid Tumors

      Columbus, Ohio
      Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Symptomatic Brain Metastases, Cardiovascular Disease, Active Infections, Others

      500 Participants Needed

      Autologous LN-145 for Lung Cancer

      Columbus, Ohio
      This trial tests LN-145, a treatment using a patient's own lab-prepared immune cells, in patients with advanced lung cancer that has spread. The process includes reducing existing immune cells, infusing enhanced ones, and boosting their activity.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Organ Transplant, Others
      Must Be Taking:Platinum-based Chemotherapy

      170 Participants Needed

      Ibuzatrelvir for Coronavirus

      Columbus, Ohio
      The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12 - 18

      Key Eligibility Criteria

      Disqualifiers:Severe Renal Impairment, Active Liver Disease, Others
      Must Not Be Taking:Antivirals, COVID-19 MAbs

      2330 Participants Needed

      Multiple Treatments for Pneumonia

      Columbus, Ohio
      REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Healthcare-associated Pneumonia, Imminent Death, Others

      20000 Participants Needed

      OHB-607 for Bronchopulmonary Dysplasia

      Columbus, Ohio
      This trial is testing a new medicine to see if it can prevent a serious lung condition in very premature babies. The goal is to see if this new treatment works better at protecting their lungs and reducing the chances of developing chronic lung disease.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:0 - 24

      Key Eligibility Criteria

      Disqualifiers:Congenital Malformation, Chromosomal Abnormality, Neurological Disease, Others

      338 Participants Needed

      Why Other Patients Applied

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Lung Disease Trial

      Vimseltinib for Chronic Graft-Versus-Host Disease

      Columbus, Ohio
      The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Illness, Uncontrolled Infection, Others
      Must Not Be Taking:CSF1R Inhibitors

      48 Participants Needed

      Tozorakimab for Viral Pneumonia

      Columbus, Ohio
      This trial is testing tozorakimab, a medication that may help people with severe viral lung infections who need extra oxygen. The goal is to see if it can prevent death or the need for advanced breathing support. Tozorakimab works by reducing harmful inflammation in the lungs.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 18

      Key Eligibility Criteria

      Disqualifiers:Fungal Infection, Parasitic Infection, Others

      2870 Participants Needed

      Selpercatinib for Solid Tumors

      Columbus, Ohio
      This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Oncogenic Driver, Cardiovascular Disease, Others
      Must Not Be Taking:Strong CYP3A4 Inhibitors

      857 Participants Needed

      BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

      Columbus, Ohio
      BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Resistant Mutations, Interstitial Lung Disease, Others
      Must Be Taking:EGFR TKIs

      200 Participants Needed

      Pembrolizumab + Investigational Agents for Non-Small Cell Lung Cancer

      Columbus, Ohio
      The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC that is PD-L1 positive. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01). The pembrolizumab+ MK-0482 arm was added with Amendment 6.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Small Cell Lung Cancer, CNS Metastases, Active Infection, Cardiac Disease, Others
      Must Not Be Taking:Steroids, Immunosuppressants, Chemotherapy, Others

      120 Participants Needed

      Pembrolizumab + Chemotherapy for Non-Small Cell Lung Cancer

      Columbus, Ohio
      The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Small Cell Lung Cancer, Immunodeficiency, Active CNS Metastases, Autoimmune Disease, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      450 Participants Needed

      Tabelecleucel for Post-Transplant Cancer

      Columbus, Ohio
      The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Burkitt Lymphoma, Hodgkin Lymphoma, Others
      Must Not Be Taking:Daily Steroids, Methotrexate

      115 Participants Needed

      mHealth Intervention for Cancer

      Columbus, Ohio
      In response to the symptom needs experienced in advanced cancer, the investigators developed a brief, integrated CBT-ACT symptom management intervention, Finding Our Center Under Stress (FOCUS). Using FOCUS, participants learn skills to self-manage sleep, worry-anxiety, depression, and fatigue and improve their ability to focus on what matters most to them despite these symptoms. Results of the pilot randomized controlled trial with people with advanced cancer demonstrate improved sleep on both self-report and physiologic (i.e., actigraphy) measures, and improvements on worry, depression, and fatigue interference with strong effect sizes ranging from d= 0.59 to 0.98 and sleep effects 12 months post-treatment. The investigators refined the fatigue module with exercise modifications and beta-tested the FOCUS intervention as an mHealth web-based app for acceptability with 10 diverse patients with advanced cancer -100% would recommend for other advanced cancer patients. The overall objective of this proposed randomized effectiveness trial is to evaluate the impact of this telemedicine-mHealth symptom cluster intervention with patients from rural and Appalachian communities (where the PI was raised). Innovative features include a focus on a symptom cluster including anxiety, integrated CBT-ACT intervention, telemedicine-mHealth delivery method, and biobehavioral approach evaluating behavioral and inflammatory mediators.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Night-shift Work, Untreated Bipolar, Substance Abuse, Others

      120 Participants Needed

      STAR0602 for Advanced Cancers

      Columbus, Ohio
      This trial is testing a new drug called STAR0602 to see if it is safe and effective for treating advanced cancers with specific markers. The drug is given through an IV and aims to find and destroy cancer cells by recognizing these markers. The study will first determine the best dose and then see how well the drug works in patients.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Cardiovascular, Infection, Pregnancy, Others
      Must Not Be Taking:Immune-suppressive Drugs

      365 Participants Needed

      MAGE-A4ᶜ¹º³²T Therapy for Cancer

      Columbus, Ohio
      This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Active Infection, Pregnancy, Others

      71 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Lung Disease clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Lung Disease clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Lung Disease trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Lung Disease is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Lung Disease medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Lung Disease clinical trials?

      Most recently, we added mHealth Intervention for Cancer, BNT162b2 Vaccine for COVID-19 and Nerandomilast for Interstitial Lung Disease to the Power online platform.